Care-HF CArdiac Resynchronization in Heart Failure

Medtronic

Status

Completed

Conditions

Heart Failure

Treatments

Device: Implantable Cardiac Resynchronisation (pacing) device

Study type

Interventional

Funder types

Industry

Identifiers

NCT00170300

Care-HF 2.02.02

Details and patient eligibility

About

The CARE-HF trial evaluates the effects of Cardiac Resynchronization (CR) therapy on the mortality and morbidity of patients with heart failure due to left ventricular systolic dysfunction already receiving diuretics and optimal medical therapy.

Full description

813 patients enrolled 82 centers in 12 countries (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, and UK)

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Heart failure for at least 6 weeks requiring loop diuretics
Currently in NYHA class III/IV
A high standard of pharmacological therapy
LV systolic dysfunction and dilation (EF <=35%; EDD >30mm/height in metres)
QRS >=120 ms Dyssynchrony confirmed by echo if QRS 120-149 ms (Aortic pre-ejection delay >140ms, Interventricular mechanical delay >40 ms, Delayed activation of postero-lateral LV wall)

Exclusion criteria

Age < 18 years old or age < legal age defined in the country in case different
Chronic atrial fibrillation within 6 weeks prior to randomization;
Impairment of left ventricular function not related to left ventricular systolic function
Potentially reversible forms of cardiomyopathy:
Cardiac surgery, percutaneous coronary intervention, cardiomyoplasty, myocardial infarction,unstable severe angina or stroke within 6 weeks before randomization
A conventional indication for bradyarrhythmia pacing exists;
A conventional indication for an ICD exists
A pacemaker or ICD has already been implanted;
In-Patients requiring continuous intravenous therapy for Heart Failure;
Life expectancy < 1 year for disease unrelated to Heart Failure;
Pregnancy or childbearing potential and not on reliable contraceptive;
Mechanical tricuspid valve;
Anticipated compliance problem or participation in another trial;